pipeline-prospector-insert-v1
X

Find Novel Oncology Drugs in Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GDC-0570

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ningbo NewBay Medical Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 27, 2020

            Details:

            Ningbo NewBay Medical Technology has been granted the exclusive global rights to further develop and commercialize GDC-0570.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SNP-7/8a

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 15, 2020

            Details:

            The groundbreaking peptide-based personalized cancer vaccine was shown to more efficiently induce T-cell responses against tumor neoantigens compared to traditional vaccines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T cell based therapy

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Astellas Pharma

            Deal Size: $897.5 million Upfront Cash: $50.0 million

            Deal Type: Agreement January 14, 2020

            Details:

            Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived allogeneic T-cell platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Alta Partners

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 10, 2020

            Details:

            Financing will used to discover and develop new small molecule therapies targeting acquired resistance in oncology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paclitaxel

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 10, 2020

            Details:

            The funds raised will be used to further the development of its TYN-21 program, a novel, proprietary formulation of paclitaxel

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Polypeptides

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Roche

            Deal Size: $1,540.0 million Upfront Cash: $40.0 million

            Deal Type: Licensing Agreement January 10, 2020

            Details:

            This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Centyrins

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ionis Pharmaceuticals, Inc

            Deal Size: $1,400.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 09, 2020

            Details:

            As per the agreement, the two companies have agreed to jointly work towards advancing a defined number of ASO-Centyrin drug conjugates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DKN-01,tislelizumab

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: BeiGene

            Deal Size: $162.0 million Upfront Cash: $3.0 million

            Deal Type: Licensing Agreement January 03, 2020

            Details:

            Under the terms and condition of the agreement, BeiGene is granted option to develop and commercialize Leap's DKN-01 in the Asia Pacific Region, excluding Japan.